Table 4.
Comparison of magnetic resonance imaging proton density fat fraction and visceral fat area change from baseline in different treatment groups
|
|
Studies
|
Participants
|
WMD
|
95%CI
|
P
value
|
|
| MRI-PDFF change | ||||||
| DPP-4 inhibitors | 2 | 52/49 | -2.31 | -4.92 | 0.29 | 0.08 |
| GLP-1 RAs | 1 | 24/24 | -3.20 | -5.98 | -0.42 | 0.02 |
| SGLT2 inhibitors | 2 | 65/61 | -1.18 | -2.38 | 0.03 | 0.06 |
| VFA change | ||||||
| DPP-4 inhibitors | 1 | 27/24 | -23.10 | -38.84 | -7.36 | 0.004 |
| GLP-1 RAs | 1 | 24/24 | -30.40 | -46.86 | -13.94 | 0.0003 |
| SGLT2 inhibitors | 2 | 48/50 | -23.48 | -25.85 | -21.12 | < 0.0001 |
MRI-PDFF: Magnetic resonance imaging proton density fat fraction; VAF: Visceral fat area; WMD: Weighted mean difference; CI: Confidence interval; DPP-4: Dipeptidyl peptidase-4; GLP-1 RA: Glucagon-like peptide-1 receptor agonist; SGLT2: Sodium-glucose cotransporter 2.